ESPR · As filed with the SEC
Esperion Therapeutics income statement, by fiscal year
The statement as Esperion Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|---|
| Statement | |||||
| Revenues: | |||||
| Total Revenues | 403,135 | 332,314 | 116,334 | 75,475 | 78,447 |
| Product | 159,569 | 115,725 | 78,335 | 55,863 | 40,047 |
| Collaboration Revenue | 243,566 | 216,589 | 37,999 | 19,612 | 38,400 |
| Operating expenses: | |||||
| Cost of goods sold | — | 68,601 | 43,267 | 26,967 | 14,217 |
| Cost of goods sold | 129,224 | — | — | — | — |
| Research and development | 47,852 | 46,238 | 86,107 | 118,927 | 105,975 |
| Selling, general and administrative | 165,786 | 163,073 | 142,523 | 109,082 | 184,985 |
| Total operating expenses | 342,862 | 277,912 | 271,897 | 254,976 | 305,177 |
| Income (loss) from operations | 60,273 | 54,402 | (155,563) | (179,501) | (226,730) |
| Interest expense | — | — | (58,976) | (56,810) | (46,353) |
| Interest expense | (84,604) | (59,251) | — | — | — |
| Loss on extinguishment of debt and exchange transaction | 0 | (54,918) | — | — | — |
| Other income, net | 3,490 | 8,022 | 5,291 | 2,652 | 3,975 |
| Loss before income taxes | (20,841) | — | — | — | — |
| Provision for taxes on income | 1,841 | — | — | — | — |
| Net loss | (22,682) | (51,745) | (209,248) | (233,659) | (269,108) |
| Net loss per common share - basic (in dollars per share) | (0.11) | (0.28) | (2.03) | (3.52) | (9.31) |
| Net loss per common share - diluted (in dollars per share) | (0.11) | (0.28) | (2.03) | (3.52) | (9.31) |
| Weighted-average shares outstanding - basic (in shares) | 207,865,080 | 187,181,856 | 103,106,616 | 66,407,242 | 28,902,507 |
| Weighted-average shares outstanding - diluted (in shares) | 207,865,080 | 187,181,856 | 103,106,616 | 66,407,242 | 28,902,507 |
| Other comprehensive (loss) gain: | |||||
| Unrealized gain on investments | 0 | 0 | 2 | 29 | (31) |
| Total comprehensive loss | (22,682) | (51,745) | (209,246) | (233,630) | (269,139) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.